Advertisement

The Reed-Sternberg Cell and the CD30 Antigen

  • Horst. Dürkop
  • Ute. Latza
  • Brunangelo. Falini
  • Gianpaolo. Nadali
  • Giovanni. Pizzolo
  • Harald. Stein
Part of the NATO ASI Series book series (NSSA, volume 280)

Abstract

The tumour cells of Hodgkin’s disease (HD), called Reed-Sternberg and Hodgkin cells (H-RS cells) are, in conjunction with an admixture of non-malignant cells of various types, pathognomonic for HD. In most cases, the H-RS cells account for less than 5% and in some cases for less than 1% of the total tumour mass. In classical cases, the H-RS cells are large cells with bi-lobed or poly-lobed nuclei so that the cells appear binucleated or multinucleated. It is possible that, in some cases, bona fide multinucleation does actually occur. The nuclear membrane is thick and sharply defined, and there is a very large, variously shaped, acidophilic central nucleolus surrounded by a clear halo. In the most typical example of the H-RS cell, the two nuclear lobes face each other. The non-malignant counterpart of these cells is still a matter of debate. In most cases they react with the lymphoid surface markers CD30 (Schwab et al., 1982; Stein et al., 1985) and CD70 and in some cases with CDw75, CD3, T-cell receptor ß chain (TcRß) (Dallenbach and Stein, 1989), J-chain (Stein et al., 1986) and CD20. These data, as well as the detection of immunoglobulin and T-cell receptor (TcR) rearrangements by Southern blot in some instances (Herbst et al., 1989), provide evidence for a lymphoid origin of these tumour cells. In particular, Dallenbach and Stein (1989) were able to detect TcRß on the H-RS cells of 24 of 65 cases and CD20 on the H-RS cells of 12 of 65 cases. Recently, support of these data came from Tamaru et al. (1994) who reported that in 67% of HD cases with B-cell-antigen positive H-RS cells, clonal VDJ rearrangements of the immunoglobulin heavy chain (IgH) gene were detectable; no VDJ rearrangements were detected in cases with T-cell antigen-positive H-RS cells.

Keywords

CD30 Antigen Anaplastic Large Cell Lymphoma Nerve Growth Factor Receptor sCD30 Level Peanut Agglutinin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreesen R, Brugger W, Löhr GW, Bross KJ (1989) Human macrophages can express the Hodgkin’s cell-associated antigen Ki-1 (CD30). Am J Pathol 134:187PubMedGoogle Scholar
  2. Andreesen R, Osterholz J, Löhr GW, Bross KJ (1984) A Hodgkin cell-specific antigen is expressed on a subset of auto-and alloactivated T (helper) lymphoblasts. Blood 63:1299PubMedGoogle Scholar
  3. Bilbe G, Delabie J, Brüggen J, Richener H, Asselbergs FAM, Cerletti N, Sorg C, Odink K, Tarcsay L, Wiesendanger W, de Wolf-Peeters C, Shipman R (1992) Restin: a novel intermediate filament-associated protein highly expressed in the Reed-Sternberg cells of Hodgkin’s disease. EMBO J 11:2103PubMedGoogle Scholar
  4. Bowen MA, Olsen KJ, Cheng L, Avila D, Podack ER (1993) Functional effects of CD30 on a large granular lymphoma cell line, YT. J Immunol 151:5896PubMedGoogle Scholar
  5. Boylston AW, Cosford P (1985) Growth of normal human T lymphocytes induced by monoclonal antibody to the T cell antigen receptor. Eur J Immunol 15:738PubMedCrossRefGoogle Scholar
  6. Cailleau R, Young R, Olive M, Reeves WJ (1974) Breast tumour cell lines from pleural effusions. J Natl Cancer Inst 53:661PubMedGoogle Scholar
  7. Camerini D, Walz G, Loenen WAM, Borst J, Seed B (1991) The T cell activation antigen CD27 is a member of the NGF/TNF receptor gene family. J Immunol 147:3165PubMedGoogle Scholar
  8. Carbone A, Gloghini A, Volpe R (1992) Paraffin section immunohistochemistry in the diagnosis of Hodgkin’s disease and anaplastic large cell (CD30+) lymphomas. Virchows Arch A Pathol Anat 420:527CrossRefGoogle Scholar
  9. Clark EA, Ledbetter JA (1994) How B and T cells talk to each other. Nature 367:425PubMedCrossRefGoogle Scholar
  10. Cordell JL, Falini B, Erber WN, Gosh AK, Abdulazir Z, MacDonald S, Pulford KA, Stein H, Mason DY (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219PubMedCrossRefGoogle Scholar
  11. da Costa L, Carde P, Lumbroso JD, Ricard M, Pfreundschuh M, Bosq J, Manil L, Diehl V, Parmentier C (1992) Immunoscintigraphy in Hodgkin’s disease and anaplastic large cell lymphomas: results in 18 patients using the iodine radiolabelled monoclonal antibody HRS-3. Ann Oncol 3(Suppl 4):53PubMedGoogle Scholar
  12. Dallenbach FE, Stein H (1989) Expression of T-cell-receptor ß chain in Reed-Sternberg cells. Lancet ii:828CrossRefGoogle Scholar
  13. Daus H, Trümper L, Roth J, Jacobs G, von Bonin F, Gause A, Pfreundschuh M (1994) Molecular analysis of single Reed-Sternberg cells of Hodgkin’s disease: absence of IGH and TCR rearrangements: p53 and N-RAS mutations. J Cancer Res Clin Oncol 120 (Suppl):R56Google Scholar
  14. Delabie J, Shipman R, Brüggen J, de Strooper B, van Leuven F, Tarcsay L, Cedetti N, Odink K, Diehl V, Bilbe G, de Wolf-Peeters C (1992) Expression of the novel intermediate filament-associated protein restin in Hodgkin’s disease and anaplastic large-cell lymphoma. Blood 80:2891PubMedGoogle Scholar
  15. Diehl V, Kirchner HH, Burrichter H, Stein H, Fonatsch C, Gerdes J, Schaadt M, Heit W, Uchanska-Ziegler B, Ziegler A, Heintz F, Sueno K (1982) Characteristics of Hodgkin’s disease-derived cell lines. Cancer Treat Rep 66:615PubMedGoogle Scholar
  16. Diehl V, Kirchner HH, Schaadt M, Fonatsch C, Stein H, Gerdes J, Boie, C (1981) Hodgkin’s disease, establishment and characterisation of four in vitro cell lines. J Cancer Res Clin Oncol 101:111PubMedCrossRefGoogle Scholar
  17. Dürkop H, Latza U, Hummel M, Eitelbach M, Seed B, Stein H (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 68:421PubMedCrossRefGoogle Scholar
  18. Ellis TM, Simms PE, Slivnick DJ, Jack HM, Fisher RI (1993) CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 151:2380PubMedGoogle Scholar
  19. Engelmann H, Novick D, Wallach D (1990) Two tumour necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumour necrosis factor receptors. J Biol Chem 265:1531PubMedGoogle Scholar
  20. Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, Henle W (1966) Morphological and virological investigations on cultured Burkitt tumour lymphoblasts (strain Raji). J Natl Cancer Inst 37:547PubMedGoogle Scholar
  21. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkop H, Aversa F, Cornell P, Pizzolo G, Barbabietola G, Sabattini E, Pileri S, Martelli MF, Stirpe F (1992a) Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet 339:1195PubMedCrossRefGoogle Scholar
  22. Falini B, Flenghi L, Fedeli L, Broe MK, Bonino C, Stein H, Dürkop H, Bigerna B, Barbabietola G, Venturi S, Aversa F, Pizzolo G, Bartoli A, Pileri S, Sabattini E, Palumbo R, Martelli MF (1992b) In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin’s disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol 82:38PubMedCrossRefGoogle Scholar
  23. Falini B, Flenghi L, Pasqualucci L, Bolognesi A, Tazzari PL, Pileri S, Stein H, Martelli MF, Stirpe F (1993) Therapy of refractory Hodgkin’s disease with anti-CD30/saporin immunotoxin. Tissue Antigens 42:243.Google Scholar
  24. Fonatsch C, Latza U, Dürkop H, Rieder H, Stein H (1992) Assignment of the human CD30 (Ki-1) gene to lp36. Genomics 14:825PubMedCrossRefGoogle Scholar
  25. Froese P, Lemke H, Gerdes J, Havensteen B, Schwarting R, Hansen H, Stein H (1987) Biochemical characterisation and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol 139:2081PubMedGoogle Scholar
  26. Gause A, Jung W, Schmits R, Tschiersch A, Scholz R, Pohl C, Hasenclever D, Diehl V, Pfreundschuh M (1992) Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin’s lymphoma. Ann Oncol 3(Suppl 4):49PubMedGoogle Scholar
  27. Gause A, Pohl C, Tschiersch A, da Costa L, Jung W, Diehl V, Hasenclever D, Pfreundschuh M (1991) Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin’s disease. Blood 77:1983PubMedGoogle Scholar
  28. Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP, Guccion JG (1980) Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 55:409PubMedGoogle Scholar
  29. Hall PA, D’Ardenne AJ, Stansfeld AG (1988) Paraffin section immunohistochemistry. 1. Non-Hodgkin’s lymphoma. Histopathol 13:149CrossRefGoogle Scholar
  30. Hanks SK, Quinn AM, Hunter T (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42PubMedCrossRefGoogle Scholar
  31. Hansen H, Bredfeldt G, Havsteen B, Lemke H (1990) Protein kinase activity of the intracellular but not of the membrane-associated form of the Ki-1 antigen (CD30). Res Immunol 141:13PubMedCrossRefGoogle Scholar
  32. Hansen H, Lemke H, Bredfeldt G, Könnecke I, Havsteen B (1989) The Hodgkin-associated Ki-1 antigen exists in an intracellular and a membrane-bound form. Biol Chem Hoppe-Seyler 370:409PubMedCrossRefGoogle Scholar
  33. Heller RA, Song K, Onasch M, Fischer WH, Chang D, Ringold, GM (1990) Complementary DNA cloning of a receptor for tumour necrosis factor and demonstration of a shed form of the receptor. Proc Natl Acad Sci USA 87:6151PubMedCrossRefGoogle Scholar
  34. Herbst H, Tippelmann G, Anagnostopoulos I, Gerdes J, Schwarting R, Boehm T, Pileri S, Jones DB, Stein H (1989) Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin’s disease and Ki-1-positive anaplastic large cell lymphoma: dissociation between phenotype and genotype. Leuk Res 13:103PubMedCrossRefGoogle Scholar
  35. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:33CrossRefGoogle Scholar
  36. Johnson D, Lanahan A, Buck R, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M (1986) Expression and structure of the human NGF receptor. Cell 47:545PubMedCrossRefGoogle Scholar
  37. Jones DB, Furley AJW, Gerdes J, Greaves MF, Stein H, Wright DH (1989) Phenotypic and genotypic analysis of two cell lines derived from Hodgkin’s disease tissue biopsies. In New Aspects in the Diagnosis and Treatment of Hodgkin’s disease. Diehl V, Pfreundschuh M, Loeffler M, eds (Berlin: Springer) p62Google Scholar
  38. Jones DB, Scott CS, Wright DH, Stein H, Beverley PLC, Payne SV, Crawford DH (1985) Phenotypic analysis of an established cell line derived from a patient with Hodgkin’s disease (HD). Hematol Oncol 3:133PubMedCrossRefGoogle Scholar
  39. Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (1989) Ki-1 (CD30) antigen is released by Ki-1-positive tumour cells in vitro and in vivo. I. Partial characterisation of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19:157PubMedCrossRefGoogle Scholar
  40. Kemper O, Derré J, Cherif D, Engelmann H, Wallach D, Berger R (1991) The gene for the type II (p75) tumour necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p36.3. Hum Genet 87:623PubMedCrossRefGoogle Scholar
  41. Kohno T, Brewer MT, Baker SL, Schwartz PE, King MW, Hale KK, Squires CH, Thompson RC, Vannice JL (1990) A second tumour necrosis factor receptor gene product can shed a naturally occurring tumour necrosis factor inhibitor. Proc Natl Acad Sci USA 87:8331PubMedCrossRefGoogle Scholar
  42. Kwon BS, Weissman SM (1989) cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 86:1963PubMedCrossRefGoogle Scholar
  43. Latza U, Dürkop H, Schnittger S, Ringeling J, Eitelbach F, Hummel M, Fonatsch C, Stein H (1994) The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol 24:677PubMedCrossRefGoogle Scholar
  44. Latza U, Foss HD, Dürkop H, Eitelbach F, Dieckmann KP, Loy V, Unger M, Stein H (1995) Cellular and soluble CD30 antigen in embryonal carcinoma and during embryogenesis. Am J Pathol 146:463PubMedGoogle Scholar
  45. Linsley PS, Clark EA, Ledbetter JA (1990) T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 87:5031PubMedCrossRefGoogle Scholar
  46. Loetscher H, Pan YCE, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, Lesslauer W (1990) Molecular cloning and expression of the human 55 kd tumour necrosis factor receptor. Cell 61:351PubMedCrossRefGoogle Scholar
  47. Mallett S, Barclay AN (1991) A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today 12:220PubMedCrossRefGoogle Scholar
  48. Mechtersheimer G, Möller P (1990) Expression of KM antigen (CD30) in mesenchymal tumours. Cancer 66:1732PubMedCrossRefGoogle Scholar
  49. Miettinen M (1992) CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin’s and non-Hodgkin’s lymphomas. Arch Pathol Lab Med 116:1197PubMedGoogle Scholar
  50. Morgan R, Smith SD, Hech K, Christy V, Mellenti JD, Warnke R, Cleary ML (1989) Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2:5)(p23:q35) common to malignancies with features of so-called malignant histiocytosis. Blood 73:2155PubMedGoogle Scholar
  51. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chilosi M, Menestrina F, Fiacchini M, Stein H, Pizzolo G (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol 12:793PubMedGoogle Scholar
  52. Nawrocki JF, Kirsten ES, Fisher RI (1988) Biochemical and structural properties of a Hodgkin’s disease-related membrane protein. J Immunol 141:672PubMedGoogle Scholar
  53. Norton AJ, Isaacson PG (1987) Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. Am J Pathol 128: 225PubMedGoogle Scholar
  54. Pallesen G, Hamilton-Dutoit SJ (1988) Ki-1 (CD30) antigen is regularly expressed by tumour cells of embryonal carcinoma. Am J Pathol 133:446PubMedGoogle Scholar
  55. Pearson WR, Lipman DJ (1988) Improved tools for biological sequence comparison. Proc Natl Acad Sci USA 85:2444PubMedCrossRefGoogle Scholar
  56. Perkins SL, Kjeldsberg CR (1993) Immunophenotyping of lymphomas and leukemias in paraffin-embedded tissues. Am J Clin Pathol 99:362PubMedGoogle Scholar
  57. Pfreundschuh M, Pohl C, Berenbeck C, Schroeder J, Jung W, Schmits R, Tschiersch A, Diehl V, Gause A (1990) Detection of a soluble form of the CD30 antigen in the sera of patients with lymphoma, adult T-cell leukemia, and infectious mononucleosis. Int J Cancer 45:869PubMedCrossRefGoogle Scholar
  58. Pizzolo G, Stein H, Josimovic-Alasevic O, Vinante F, Zanotti R, Chilosi M, Feller AC, Diamantstein T (1990) Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanisms. Br J Haematol 75:485PubMedCrossRefGoogle Scholar
  59. Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandini G, Sinicco A, Raiteri R, Semenzaio G, Stein H, Perona G (1994) High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of disease progression. AIDS 8:741PubMedCrossRefGoogle Scholar
  60. Ralfkiaer E, Bosq J, Gatter KC, Schwarting R, Gerdes J, Stein H, Mason DY (1987) Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res 279:285PubMedCrossRefGoogle Scholar
  61. Ree HJ, Neimann RS, Martin AW, Dallenbach F, Stein H (1989) Paraffin section markers for Reed-Sternberg cells: a comparative study of peanut agglutinin, Leu-Mi, LN-2, and Ber-H2. Cancer 63:2030PubMedCrossRefGoogle Scholar
  62. Rohde D, Hansen H, Hairier M, Lange H, Mielke V, Hansmann ML, Lemke H (1992) Cellular localisations and processing of the two molecular forms of the Hodgkin-associated Ki-1 (CD30) antigen. The protein kinase Ki-1/57 occurs in the nucleus. Am J Pathol 140:473PubMedGoogle Scholar
  63. Sarker AB, Akagi T, Jeon HJ, Miyake K, Murakami I, Yoshino T, Takahashi K, Nose S (1992) Bauhinia purpurea-a new paraffin section marker for Reed-Sternberg cells of Hodgkin’s disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30). Am J Pathol 141:19PubMedGoogle Scholar
  64. Schaadt M, Diehl V, Stein H, Fonatsch C, Kirchner HH (1980) Two neoplastic cell lines with unique features derived from Hodgkin’s disease. Int J Cancer 26:723PubMedCrossRefGoogle Scholar
  65. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GHW, Gatanaga T, Granger GA, Lentz R, Raab H, Kohr W, Goeddel DV (1990) Molecular cloning and expression of a receptor for human tumour necrosis factor. Cell 61:361PubMedCrossRefGoogle Scholar
  66. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature 299:65PubMedCrossRefGoogle Scholar
  67. Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H (1989) BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74:1678PubMedGoogle Scholar
  68. Smith C, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RG (1990) A receptor for tumour necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019PubMedCrossRefGoogle Scholar
  69. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, Grabstein KH, Gliniak B, McAlister IB, Fanslow W, Anderson M, Falk B, Gimpel S, Gillis S, Din WS, Goodwin RG, Armitage RJ (1993) CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349PubMedCrossRefGoogle Scholar
  70. Stamenkovic I, Clark EA, Seed B (1989) A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 8:1403PubMedGoogle Scholar
  71. Stein H, Dallenbach F (1992) Diffuse large cell lymphomas of B and T cell type. In Neoplastic Hematology. Knowles DM, ed (Baltimore: William & Wilkins) p675Google Scholar
  72. Stein H, Hansmann ML, Lennert K, Brandtzaeg P, Gatter KC, Mason DY (1986) Reed-Sternberg cells in lymphocyte-predominant Hodgkin’s disease of nodular subtype contain J chain. Am J Pathol 86:292Google Scholar
  73. Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848PubMedGoogle Scholar
  74. Sundström C, Nilsson K (1976) Establishment and characterisation of a human histiocytic lymphoma cell line(U-937). Int J Cancer 17:565PubMedCrossRefGoogle Scholar
  75. Tamaru J, Hummel M, Zemlin M, Kalvelage B, Stein H (1994) Hodgkin’s disease with a B cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 84:708PubMedGoogle Scholar
  76. van der Putte SCJ, Toonstra J, van Wichen DF, van Unnik JAM, van Vloten WA (1988) The expression of the Hodgkin’s disease-associated antigen Ki-1 in cutaneous infiltrates. Acta Derm Venereol (Stockholm) 68:202Google Scholar
  77. Vinante F, Morosato L, de Sabata D, Pizzolo G (1991) Soluble molecules in lymphoproliferative disorders. Leukemia 5(Suppl 1): 18PubMedGoogle Scholar
  78. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M, Uchiyama T, Maeda M (1985) TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol 134:1623PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Horst. Dürkop
    • 1
  • Ute. Latza
    • 1
  • Brunangelo. Falini
    • 2
  • Gianpaolo. Nadali
    • 3
  • Giovanni. Pizzolo
    • 3
  • Harald. Stein
    • 1
  1. 1.Institute of Pathology, Klinikum SteglitzFree University of BerlinGermany
  2. 2.Institute of HematologyPerugia UniversityItaly
  3. 3.Department of Hematology, Policlinico Borgo RomaVerona University School of MedicineItaly

Personalised recommendations